Erinjeri, J. P., Beg, M. S., Bouattour, M., Ren, Z., Sangro, B., Chan, S. L., Breder, V. V., Chiu, C., Decaens, T., Heo, J., Griffin, R., Ali, S., Balaji, K., Kudo, M. (2025). Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: A phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4083